Literature DB >> 7592170

The sensitivity of Leishmania species to aminosidine.

R A Neal1, S Allen, N McCoy, P Olliaro, S L Croft.   

Abstract

The aminoglycoside, aminosidine exhibited ED50S of between 1 and 5 microM against the amastigotes of Leishmania major and Leishmania tropica in mouse peritoneal macrophages whereas other strains causing New World cutaneous leishmaniasis such as Leishmania braziliensis were more refractory. Aminosidine was also active against all but one of the Leishmania donovani strains tested and when combined with sodium stibogluconate, the drug showed marked potentiation against the amastigotes of L. donovani in vitro and an additive effect in experimentally infected BALB/c mice.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7592170     DOI： 10.1093/jac/35.5.577

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  28 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis.

Authors:  E C Torres-Santos; D L Moreira; M A Kaplan; M N Meirelles; B Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

4.  Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.

Authors:  Marta Gontijo Aguiar; Aline Márcia Machado Pereira; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

5.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.

Authors:  Samuel Vidal Mussi; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

7.  Novel compounds active against Leishmania major.

Authors:  Stephanie St George; Jeanette V Bishop; Richard G Titus; Claude P Selitrennikoff
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 8.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

9.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

10.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.